- Home
- Companies
- IONIQ Sciences, Inc.
- News
- IONIQ Presents Lung Cancer Trial ...
IONIQ Presents Lung Cancer Trial Results at ATS 2022
Source: IONIQ Sciences, Inc.
- By: Shelby Moyes BatisSalt Lake City, UT -- IONIQ Sciences is proud of our team members who presented our latest lung cancer clinical trial results in a poster today at the American Thoracic Society meeting in San Francisco, CA. This was a great honor to highlight our growing bioimpedance clinical evidence that continues to demonstrate the possibility of a non-invasive, low-cost, early-stage lung cancer diagnosis.
Furthermore, the clinical evidence across different cancer types continues to prove that early detection saves money and lives. When cancer can be diagnosed in the earliest and most treatable stages, survival rates are ~90%. Early detection matters most and IONIQ Sciences is focused on making it a reality with our non-invasive bioimpedance technology. Watch us modernize early-stage cancer detection.
-
Most popular related searches
Customer comments
No comments were found for IONIQ Presents Lung Cancer Trial Results at ATS 2022. Be the first to comment!